ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Adalimumab

Also written as “adalimumab”, “MSB11022” and “M923”.

Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Crohn Disease · Colitis, Ulcerative · Hidradenitis Suppurativa, led by 17 companies.

Drug pageAdalimumab: every studyMany companies study it; this page follows only the 149 they lead. All 319 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 2005149 company-led studies, 7 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbott620 open or runningphase 4since Sep 13, 2005Nov 1, 2002none ahead
AbbVieits history only543 open or runningphase 4since May 25, 2010Sep 13, 2005Sep 2027phase 2 · NCT06257875
Alvotech Swissits history only60 open or runningphase 3since Feb 5, 2019Jun 8, 2018none ahead
Johnson & Johnsonits history only50 open or runningphase 3since Dec 18, 2013Dec 18, 2013none ahead
Fresenius Kabiits history only40 open or runningphase 3since Jan 17, 2016Jan 17, 2016none ahead
Biocadits history only30 open or runningphase 3since Mar 31, 2016Mar 16, 2015none ahead
Cinnagenits history only20 open or runningphase 3since May 24, 2017May 24, 2017none ahead
Sino Biopharmaceuticalits history only22 open or runningphase 4since Apr 8, 2026Apr 8, 2026Apr 2028phase 4 · NCT07529925
Takedaits history only20 open or runningphase 4since May 5, 2016Mar 15, 2015none ahead
Viatrisits history only20 open or runningphase 3since Nov 9, 2015Jun 3, 2015none ahead

Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany, Mylan, Pharm-Olam, PPD DEVELOPMENT, LP, PRA Health Sciences, IST GmbH, Germany, Parexel, Pivotal S.L., GlaxoSmithKline, Regeneron Pharmaceuticals, Eisai and Abbott Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Abbott only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 37 studies since Mar 3, 2003.

  1. Oct 1, 2007Phase 3 study in Arthritis, RheumatoidNCT00538902 · 302 enrolled · China
  2. Dec 1, 2007Phase 3 study in PsoriasisNCT00566722 · 152 enrolled · United States, Canada
  3. Jan 10, 2008Phase 3 study in Arthritis, RheumatoidNCT00603993 · 88 enrolled · Japan
  4. Mar 25, 20085 phase 2 studiesNCT00645892, NCT00646386, NCT00646191 and 2 more
  5. Mar 26, 20085 phase 3 studiesNCT00646178, NCT00647491, NCT00647400 and 2 more
  6. Mar 28, 2008Phase 4 study in Arthritis, RheumatoidNCT00649922 · 226 enrolled
  7. Apr 24, 2008Phase 3 study in Spondylitis, AnkylosingNCT00667355 · 41 enrolled · Japan
  8. Jun 2, 2008Phase 3 study in Arthritis, JuvenileNCT00690573 · 25 enrolled · Japan
  9. Aug 13, 2008Phase 4 study in PsoriasisNCT00735787 · 81 enrolled · United States, Canada
  10. Sep 25, 2008Phase 4 study in Arthritis, RheumatoidNCT00761514 · 14 enrolled · Puerto Rico
  11. Mar 26, 2009Phase 3 study in Arthritis, RheumatoidNCT00870467 · 334 enrolled · Japan
  12. Apr 30, 2009Phase 2 study in Hidradenitis SuppurativaNCT00918255 · 154 enrolled · United States, Denmark, Germany and more
  13. Feb 5, 20102 phase 3 studiesNCT01114880, NCT01070303
  14. Oct 28, 2010Phase 3 study in Arthritis, RheumatoidNCT01231321 · 100 enrolled · Russian Federation
  15. Dec 9, 2017Named adalimumabINNProposed as its International Nonproprietary Name in WHO's List 118 · before, MSB11022, M923

TargetBeta

TNF →read by rule
“TNF-alpha inhibitor”ChEMBL 37, by rule

Other programs on TNF

ProgramCompanyFurthest phaseStudies
Brentuximab VedotinrulePfizerphase 437
CHS-1420rulenanjing-king-friend-biochemical-pharmaceutical-co-ltdphase 32
brivekimigSanofiphase 26
Hadlimarulebiora-therapeutics-incphase 11

Studies

The newest 60 of 62 Abbott leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT01231321Arthritis, Rheumatoid · Russian Federation3CompletedFeb 2010100
NCT01070303Crohn Disease · United States3CompletedDec 2008177
NCT01114880Spondylitis, Ankylosing · China3CompletedSep 2010344
NCT00918255Hidradenitis Suppurativa · United States, Denmark, Germany and more2CompletedMar 2010154
NCT00870467Arthritis, Rheumatoid · Japan3CompletedMar 2011334
NCT00761514Arthritis, Rheumatoid · Puerto Rico4TerminatedAug 200814
NCT00735787Psoriasis · United States, Canada4CompletedSep 200981
NCT00690573Arthritis, Juvenile · Japan3CompletedMar 201025
NCT00667355Spondylitis, Ankylosing · Japan3CompletedMay 200941
NCT00649922Arthritis, Rheumatoid4CompletedDec 2004226
NCT00647920Arthritis, Rheumatoid · Taiwan3CompletedApr 200547
NCT00647491Arthritis, Rheumatoid · Japan3CompletedJun 2005352
NCT00647400Psoriasis · Japan3CompletedSep 2007147
NCT00647270Arthritis, Rheumatoid · United States, Australia, Canada and more3CompletedApr 2009420
NCT00646386Arthritis2CompletedApr 2004315
NCT00646191Psoriasis2CompletedJun 2004137
NCT00646178Arthritis3CompletedMar 2004102
NCT00645905Psoriasis2CompletedMar 2005148
NCT00645814Psoriasis2CompletedSep 2003148
NCT00645892Psoriasis2CompletedSep 200432
NCT00603993Arthritis, Rheumatoid · Japan3CompletedNov 200688
NCT00566722Psoriasis · United States, Canada3CompletedApr 2009152
NCT00538902Arthritis, Rheumatoid · China3CompletedJul 2008302
NCT00513370Psoriasis · Canada3CompletedSep 2008203
NCT00512863Asthma2Withdrawn272
NCT00478660Spondylitis, Ankylosing · Austria, Belgium, Denmark and more3Completed1,250
NCT00448383Arthritis, Rheumatoid3CompletedNov 20046,610
NCT00445939Crohn Disease · Japan3CompletedDec 200790
NCT00445432Crohn Disease · Japan3CompletedMar 200982
NCT00427921Crohn Disease · United States3CompletedJan 2008304
NCT00427362Arthritis, Psoriatic3CompletedMay 2007127
NCT00420927Arthritis, Rheumatoid · United States, Argentina, Australia and more4CompletedJul 20101,032
NCT00409682Crohn Disease · United States, Belgium, Canada and more3CompletedMay 2010192
NCT00409617Crohn Disease · Austria, Belgium, Czech Republic and more3CompletedJul 2008945
NCT00408629Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedMar 2010518
NCT00385736Colitis, Ulcerative · United States, Austria, Belgium and more3CompletedApr 2009576
NCT00348283Crohn Disease · United States, Austria, Belgium and more3CompletedSep 2008135
NCT00338650Crohn Disease · United States3Completed1,000
NCT00237887Psoriasis3Completed1,212
NCT00235885Arthritis, Psoriatic · United States3Completed445
NCT00235872Arthritis, Rheumatoid · Japan3CompletedJul 2006309
NCT00235859Arthritis, Rheumatoid3Completed128
NCT00235833Arthritis, Rheumatoid · Japan2CompletedOct 200425
NCT00235820Psoriasis · United States3CompletedMay 2006271
NCT00234936Arthritis, Rheumatoid3Completed200
NCT00195819Spondylitis, Ankylosing · Canada3CompletedOct 200482
NCT00234897Arthritis, Rheumatoid · United States4Completed1,938
NCT00234845Arthritis, Rheumatoid · United States3Completed148
NCT00233571Arthritis, Rheumatoid3CompletedJun 2006796
NCT00233558Arthritis, Rheumatoid · United States4Terminated160
NCT00195715Crohn Disease · United States, Australia, Belgium and more3CompletedMar 2006777
NCT00195702Arthritis, Rheumatoid · United States, Canada3CompletedSep 2002619
NCT00195689Arthritis, Psoriatic · United States3Completed400
NCT00195676Psoriasis · United States, Austria, Belgium and more3CompletedOct 20091,469
NCT00195650Arthritis, Rheumatoid · United States, Canada3CompletedMay 2011846
NCT00105300Crohn Disease · United States, Belgium, Canada and more3Completed300
NCT00085644Spondylitis, Ankylosing · United States3CompletedDec 2004315
NCT00077779Crohn Disease · United States3Completed854
NCT00055523Crohn Disease · United States2Completed300
NCT00055497Crohn Disease · United States3CompletedJan 2005276

How it is read

Names in the registry

  • “Adalimumab”, 69 entries
  • “adalimumab”, 63 entries
  • “MSB11022”, 3 entries
  • “M923”, 3 entries
  • “Humira (adalimumab)”, 3 entries

Codes read as this program: AVT02.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.